SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

Desitin Arzneimittel GmbH750 enrolled

Overview

The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.

Study Type

OBSERVATIONAL

Enrollment

750

Conditions

Parkinson's Disease

Interventions

PiribedilDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients 18 years and older. * Indication: Morbus Parkinson. * Treatment with piribedil for the first time. * Monotherapy with piribedil. * Combination therapy with L-Dopa (from the beginning or secondary in combination with other antiparkinsonian drugs). Exclusion Criteria:

Locations (2)

Medical Practice for Neurology

Dresden, Germany

Medical Practice for Neurology

Wedel, Germany

Outcomes

Primary Outcomes

to monitor use in daily routine practice including adverse events

Time frame: 3 months

Secondary Outcomes

to monitor use in daily routine practice including efficacy aspects

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.